Related Publications

Kasturi SP, Kozlowski PA, Nakaya HI, Bürger MC, Russo P, Pham M, et al. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques. J Virol. 2017;91(4).
Bowen JR, Quicke KM, Maddur MS, O'Neal JT, McDonald CE, Fedorova NB, et al. Zika Virus Antagonizes Type I Interferon Responses during Infection of Human Dendritic Cells. PLoS Pathog. 2017;13(2):e1006164.
Laher F, Ranasinghe S, Porichis F, Mewalal N, Pretorius K, Ismail N, et al. HIV Controllers Exhibit Enhanced Frequencies of Major Histocompatibility Complex Class II Tetramer(+) Gag-Specific CD4(+) T Cells in Chronic Clade C HIV-1 Infection. J Virol. 2017;91(7).
Ranasinghe S, Lamothe PA, Soghoian DZ, Kazer SW, Cole MB, Shalek AK, et al. Antiviral CD8(+) T Cells Restricted by Human Leukocyte Antigen Class II Exist during Natural HIV Infection and Exhibit Clonal Expansion. Immunity. 2016;45(4):917-930.
Iyer SS, Gangadhara S, Victor B, Shen X, Chen X, Nabi R, et al. Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques. J Virol. 2016;90(19):8842-54.
Caskey M, Klein F, Nussenzweig MC. Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy. N Engl J Med. 2016;375(21):2019-2021.
Ho IY, Bunker JJ, Erickson SA, Neu KE, Huang M, Cortese M, et al. Refined protocol for generating monoclonal antibodies from single human and murine B cells. J Immunol Methods. 2016;438:67-70.
Gunn BM, Schneider JR, Shansab M, Bastian AR, Fahrbach KM, Smith AD, et al. Enhanced binding of antibodies generated during chronic HIV infection to mucus component MUC16. Mucosal Immunol. 2016;9(6):1549-1558.
Reese TA, Bi K, Kambal A, Filali-Mouhim A, Beura LK, Bürger MC, et al. Sequential Infection with Common Pathogens Promotes Human-like Immune Gene Expression and Altered Vaccine Response. Cell Host Microbe. 2016;19(5):713-9.
Bancroft T, Dillon MB, Antunes Rd, Paul S, Peters B, Crotty S, et al. Th1 versus Th2 T cell polarization by whole-cell and acellular childhood pertussis vaccines persists upon re-immunization in adolescence and adulthood. Cell Immunol. 2016;304-305:35-43.
Bournazos S, Gazumyan A, Seaman MS, Nussenzweig MC, Ravetch JV. Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency. Cell. 2016;165(7):1609-20.
Quicke KM, Bowen JR, Johnson EL, McDonald CE, Ma H, O'Neal JT, et al. Zika Virus Infects Human Placental Macrophages. Cell Host Microbe. 2016;20(1):83-90.
Barouch DH, Ghneim K, Bosche WJ, Li Y, Berkemeier B, Hull M, et al. Rapid Inflammasome Activation following Mucosal SIV Infection of Rhesus Monkeys. Cell. 2016;165(3):656-67.
Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP, Buckley N, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522(7557):487-91.
Galimidi RP, Klein JS, Politzer MS, Bai S, Seaman MS, Nussenzweig MC, et al. Intra-Spike Crosslinking Overcomes Antibody Evasion by HIV-1. Cell. 2015;160(3):433-46.
Yamada DH, Elsaesser H, Lux A, Timmerman JM, Morrison SL, de la Torre JC, et al. Suppression of Fcγ-receptor-mediated antibody effector function during persistent viral infection. Immunity. 2015;42(2):379-90.
Wang TT, Ravetch JV. Immune complexes: not just an innocent bystander in chronic viral infection. Immunity. 2015;42(2):213-5.
Wieland A, Shashidharamurthy R, Kamphorst AO, Han J-, Aubert RD, Choudhury BP, et al. Antibody effector functions mediated by Fcγ-receptors are compromised during persistent viral infection. Immunity. 2015;42(2):367-78.
Radebe M, Gounder K, Mokgoro M, Ndhlovu ZM, Mncube Z, Mkhize L, et al. Broad and persistent Gag-specific CD8+ T-cell responses are associated with viral control but rarely drive viral escape during primary HIV-1 infection. AIDS. 2015;29(1):23-33.
Sharma D, Priyadarshini P, Vrati S. Unraveling the web of viroinformatics: computational tools and databases in viral research. J Virol. 2014.
Gao F, Bonsignori M, Liao H-, Kumar A, Xia S-, Lu X, et al. Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies. Cell. 2014;158(3):481-91.
Ravindran R, Khan N, Nakaya HI, Li S, Loebbermann J, Maddur MS, et al. Vaccine activation of the nutrient sensor GCN2 in dendritic cells enhances antigen presentation. Science. 2014;343(6168):313-7.
Penaloza-MacMaster P, Provine NM, Ra J, Borducchi EN, McNally A, Simmons NL, et al. Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors. J Virol. 2013;87(3):1373-84.
Goulder PJ, Walker BD. HIV and HLA Class I: An Evolving Relationship. Immunity. 2012;37(3):426-40.
Walker BD, McMichael A. The T-Cell Response to HIV. Cold Spring Harb Perspect Med. 2012.
Micci L, Cervasi B, Ende ZS, Iriele RI, Reyes-Aviles E, Vinton C, et al. Paucity of interleukin (IL-21)-producing CD4+ T-cells is associated with Th17 cell depletion in SIV-infection of rhesus macaques. Blood. 2012.
Brenchley JM, Vinton C, Tabb B, Hao X, Connick E, Paiardini M, et al. Differential infection patterns of CD4+ T cells and lymphoid tissue viral burden distinguish progressive and nonprogressive lentiviral infections. Blood. 2012.
Matthews PC, Koyanagi M, Kløverpris HN, Harndahl M, Stryhn A, Akahoshi T, et al. Differential clade-specific HLA-B*3501 association with HIV-1 disease outcome is linked to immunogenicity of a single Gag epitope. J Virol. 2012.
Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature. 2012.
Stephenson KE, Li H, Walker BD, Michael NL, Barouch DH. Gag-Specific Cellular Immunity Determines In Vitro Viral Inhibition and In Vivo Virologic Control following Simian Immunodeficiency Virus Challenges of Vaccinated Rhesus Monkeys. J Virol. 2012;86(18):9583-9.
Li Y, O'Dell S, Wilson R, Wu X, Schmidt SD, Hogerkorp C-, et al. HIV-1 Neutralizing Antibodies Display Dual Recognition of the Primary and Coreceptor Binding Sites and Preferential Binding to Fully Cleaved Envelope Glycoproteins. J Virol. 2012;86(20):11231-41.
Mackelprang RD, Baeten JM, Donnell D, Celum C, Farquhar C, de Bruyn G, et al. Quantifying Ongoing HIV-1 Exposure in HIV-1-Serodiscordant Couples to Identify Individuals With Potential Host Resistance to HIV-1. J Infect Dis. 2012;206(8):1299-1308.
Barouch DH, Klasse P, Dufour J, Veazey RS, Moore JP. Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. Proc Natl Acad Sci USA. 2012;109(22):8694-8.
Angin M, Kwon DS, Streeck H, Wen F, King M, Rezai A, et al. Preserved function of regulatory T cells in chronic HIV-1 infection despite decreased numbers in blood and tissue. J Infect Dis. 2012;205(10):1495-500.
Dyavar Shetty R, Velu V, Titanji K, Bosinger SE, Freeman GJ, Silvestri G, et al. PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. J Clin Invest. 2012;122(5):1712-6.
Mouquet H, Nussenzweig MC. Polyreactive antibodies in adaptive immune responses to viruses. Cell Mol Life Sci. 2012;69(9):1435-45.
Wu X, Wang C, O'Dell S, Li Y, Keele BF, Yang Z, et al. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. J Virol. 2012;86(10):5844-56.
Chahroudi A, Bosinger SE, Vanderford TH, Paiardini M, Silvestri G. Natural SIV hosts: showing AIDS the door. Science. 2012;335(6073):1188-93.
Chahroudi A, Silvestri G. IRIS: the unfortunate rainbow of HIV. Blood. 2012;119(13):2971-2.
Porichis F, Kaufmann DE. Role of PD-1 in HIV pathogenesis and as target for therapy. Curr HIV/AIDS Rep. 2012;9(1):81-90.
Montero M, Gulzar N, Klaric K-, Donald JE, Lepik C, Wu S, et al. Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane. J Virol. 2012;86(6):2930-41.
Dosenovic P, Soldemo M, Scholz JL, O'Dell S, Grasset EK, Pelletier N, et al. BLyS-mediated modulation of naive B cell subsets impacts HIV Env-induced antibody responses. J Immunol. 2012;188(12):6018-26.
Stephenson KE, Hural J, Buchbinder SP, Sinangil F, Barouch DH. Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials. J Infect Dis. 2012;205(12):1806-10.
Vanderford TH, Slichter C, Rogers KA, Lawson BO, Obaede R, Else JG, et al. Treatment of SIV-infected sooty mangabeys with a type-I IFN agonist results in decreased virus replication without inducing hyperimmune activation. Blood. 2012;119(24):5750-7.
Kwon DS, Angin M, Hongo TC, Law KM, Johnson J, Porichis F, et al. CD4+ CD25+ regulatory T cells impair HIV-1-specific CD4 T cell responses by upregulating interleukin-10 production in monocytes. J Virol. 2012;86(12):6586-94.
Moldt B, Shibata-Koyama M, Rakasz EG, Schultz N, Kanda Y, Dunlop CD, et al. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J Virol. 2012;86(11):6189-96.
Klein F, Gaebler C, Mouquet H, Sather ND, Lehmann C, Scheid JF, et al. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J Exp Med. 2012;209(8):1469-79.
Walker BD. "Elite controllers" provide clues to keeping HIV infection in check. Interview by Tracy Hampton. JAMA. 2012;308(4):328-9.
Kovacs JM, Nkolola JP, Peng H, Cheung A, Perry J, Miller CA, et al. HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc Natl Acad Sci USA. 2012;109(30):12111-6.
West AP, Diskin R, Nussenzweig MC, Bjorkman PJ. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc Natl Acad Sci USA. 2012;109(30):E2083-90.
Burton DR, Poignard P, Stanfield RL, Wilson IA. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science. 2012;337(6091):183-6.
Depetris RS, Julien J-, Khayat R, Lee J, Pejchal R, Katpally U, et al. Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers. J Biol Chem. 2012;287(29):24239-54.
Sundling C, Li Y, Huynh N, Poulsen C, Wilson R, O'Dell S, et al. High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site. Sci Transl Med. 2012;4(142):142ra96.
Feinberg MB, Ahmed R. Born this way? Understanding the immunological basis of effective HIV control. Nat Immunol. 2012;13(7):632-4.
Guenaga J, Wyatt RT. Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function. PLoS Pathog. 2012;8(7):e1002806.
Mir KD, Bosinger SE, Gasper M, Ho O, Else JG, Brenchley JM, et al. Simian immunodeficiency virus-induced alterations in monocyte production of tumor necrosis factor alpha contribute to reduced immune activation in sooty mangabeys. J Virol. 2012;86(14):7605-15.
Chen H, Ndhlovu ZM, Liu D, Porter LC, Fang JW, Darko S, et al. TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat Immunol. 2012;13(7):691-700.
Frahm N, DeCamp AC, Friedrich DP, Carter DK, Defawe OD, Kublin JG, et al. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest. 2012;122(1):359-67.
Ahmed FK, Clark BE, Burton DR, Pantophlet R. An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site. Vaccine. 2012;30(5):922-30.
Mouquet H, Warncke M, Scheid JF, Seaman MS, Nussenzweig MC. Enhanced HIV-1 neutralization by antibody heteroligation. Proc Natl Acad Sci USA. 2012;109(3):875-80.
Nakaya HI, Pulendran B. Systems vaccinology: its promise and challenge for HIV vaccine development. Curr Opin HIV AIDS. 2012;7(1):24-31.
Wilkinson P, Filali-Mouhim A, Li S, Ahlers J, Schatzle J, Pulendran B, et al. An open-ended plea for the development of a global database of HIV vaccine responses. Curr Opin HIV AIDS. 2012;7(1):10-6.
Youngblood B, Wherry JE, Ahmed R. Acquired transcriptional programming in functional and exhausted virus-specific CD8 T cells. Curr Opin HIV AIDS. 2012;7(1):50-7.
Sekaly R-, Pulendran B. Systems biology in understanding HIV pathogenesis and guiding vaccine development. Curr Opin HIV AIDS. 2012;7(1):1-3.
Klatt NR, Silvestri G. CD4+ T cells and HIV: A paradoxical Pas de Deux. Sci Transl Med. 2012;4(123):123ps4.
Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 2012;482(7383):89-93.
Feng Y, McKee K, Tran K, O'Dell S, Schmidt SD, Phogat A, et al. Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site. J Biol Chem. 2012;287(8):5673-86.
Angin M, King M, Altfeld M, Walker BD, Wucherpfennig KW, Addo MM. Identification of HIV-1-specific regulatory T cells using HLA class II tetramers. AIDS. 2012.
Defawe OD, Fong Y, Vasilyeva E, Pickett M, Carter DK, Gabriel E, et al. Optimization and qualification of a multiplex bead array to assess cytokine and chemokine production by vaccine-specific cells. J Immunol Methods. 2012;382(1-2):117-28.
Zeng M, Paiardini M, Engram JC, Beilman GJ, Chipman JG, Schacker TW, et al. Critical role of CD4 T cells in maintaining lymphoid tissue structure for immune cell homeostasis and reconstitution. Blood. 2012;120(9):1856-67.
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410.
Stephenson KE, Sanmiguel A, Simmons NL, Smith K, Lewis MG, Szinger JJ, et al. Full-Length HIV-1 Immunogens Induce Greater Magnitude and Comparable Breadth of T Lymphocyte Responses to Conserved HIV-1 Regions Compared With Conserved-Region-Only HIV-1 Immunogens in Rhesus Monkeys. J Virol. 2012.
Kløverpris HN, Harndahl M, Leslie AJ, Carlson JM, Ismail N, van der Stok M, et al. HIV control through a single nucleotide on the HLA-B locus. J Virol. 2012.
McElrath JM, Walker BD. Is an HIV vaccine possible? J Acquir Immune Defic Syndr. 2012;60 Suppl 2:S41-3.
Doehle BP, Chang K, Fleming L, McNevin J, Hladik F, McElrath JM, et al. Vpu-Deficient HIV Strains Stimulate Innate Immune Signaling Responses in Target Cells. J Virol. 2012;86(16):8499-506.
Liu J, Li H, Iampietro JM, Barouch DH. Accelerated heterologous adenovirus prime-boost SIV vaccine in neonatal rhesus monkeys. J Virol. 2012;86(15):7829-35.
Boliar S, Murphy MK, Tran CT, Carnathan DG, Armstrong WS, Silvestri G, et al. B-lymphocyte dysfunction in chronic HIV-1 infection does not prevent cross-clade neutralization breadth. J Virol. 2012;86(15):8031-40.
Mir KD, Mavigner M, Silvestri G. The myeloid cytokine network in AIDS pathogenesis. Cytokine Growth Factor Rev. 2012;23(4-5):223-31.
Doria-Rose NA, Georgiev I, O'Dell S, Chuang G-, Staupe RP, McLellan JS, et al. A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. J Virol. 2012;86(15):8319-23.
Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol. 2012;12(8):607-14.
Doehle BP, Chang K, Rustagi A, McNevin J, McElrath JM, Gale M. Vpu Mediates Depletion of Interferon Regulatory Factor 3 during HIV Infection by a Lysosome-Dependent Mechanism. J Virol. 2012;86(16):8367-74.
Haynes BF, Gilbert PB, McElrath JM, Zolla-Pazner S, Tomaras GD, Alam MS, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366(14):1275-86.
Falkowska E, Ramos A, Feng Y, Zhou T, Moquin S, Walker LM, et al. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J Virol. 2012;86(8):4394-403.
Pattacini L, Mize GJ, Graham JB, Fluharty TR, Graham TM, Lingnau K, et al. A Novel HIV Vaccine Adjuvanted by IC31 Induces Robust and Persistent Humoral and Cellular Immunity. PLoS ONE. 2012;7(7):e42163.
Cheng C, Wang L, Wang LS, Gall JG, Nason M, Schwartz RM, et al. Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination. PLoS ONE. 2012;7(4):e33969.
Janes H, Frahm N, DeCamp AC, Rolland M, Gabriel E, Wolfson J, et al. MRKAd5 HIV-1 Gag/Pol/Nef Vaccine-Induced T-Cell Responses Inadequately Predict Distance of Breakthrough HIV-1 Sequences to the Vaccine or Viral Load. PLoS ONE. 2012;7(8):e43396.
Wright JK, Brumme ZL, Julg B, van der Stok M, Mncube Z, Gao X, et al. Lack of association between HLA class II alleles and in vitro replication capacities of recombinant viruses encoding HIV-1 subtype C Gag-protease from chronically infected individuals. J Virol. 2012;86(2):1273-6.
Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien J-, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011;477(7365):466-70.
Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 2011;333(6049):1633-7.
De Rosa SC, Thomas EP, Bui J, Huang Y, DeCamp AC, Morgan C, et al. HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. J Immunol. 2011;187(6):3391-401.
Li Y, O'Dell S, Walker LM, Wu X, Guenaga J, Feng Y, et al. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol. 2011;85(17):8954-67.
Bernstein A, Pulendran B, Rappuoli R. Systems vaccinomics: the road ahead for vaccinology. OMICS. 2011;15(9):529-31.
Walker BD, Ahmed R, Plotkin S. Moving ahead an HIV vaccine: use both arms to beat HIV. Nat Med. 2011;17(10):1194-5.
Pejchal R, Doores KJ, Walker LM, Khayat R, Huang P-, Wang S-, et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science. 2011;334(6059):1097-103.
Harris A, Borgnia MJ, Shi D, Bartesaghi A, He H, Pejchal R, et al. Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc Natl Acad Sci USA. 2011;108(28):11440-5.
Mörner A, Jansson M, Bunnik EM, Schøller J, Vaughan R, Wang Y, et al. Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques. J Virol. 2011;85(13):6442-52.
Bhanich Supapol W, Remis RS, Raboud J, Millson M, Tappero JW, Kaul R, et al. Prevalence and correlates of GB virus C infection in HIV-infected and HIV-uninfected pregnant women in Bangkok, Thailand. J Med Virol. 2011;83(1):33-44.
Diskin R, Scheid JF, Marcovecchio PM, West AP, Klein F, Gao H, et al. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science. 2011;334(6060):1289-93.
Stanfield RL, Julien J-, Pejchal R, Gach JS, Zwick MB, Wilson IA. Structure-based design of a protein immunogen that displays an HIV-1 gp41 neutralizing epitope. J Mol Biol. 2011;414(3):460-76.
McLellan JS, Pancera M, Carrico C, Gorman J, Julien J-, Khayat R, et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature. 2011;480(7377):336-43.
Walker LM, Sok D, Nishimura Y, Donau O, Sadjadpour R, Gautam R, et al. Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque. Proc Natl Acad Sci USA. 2011;108(50):20125-9.
Mouquet H, Klein F, Scheid JF, Warncke M, Pietzsch J, Oliveira TY, et al. Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses. PLoS ONE. 2011;6(9):e24078.
Lingappa JR, Petrovski S, Kahle E, Fellay J, Shianna K, McElrath JM, et al. Genomewide association study for determinants of HIV-1 acquisition and viral set point in HIV-1 serodiscordant couples with quantified virus exposure. PLoS ONE. 2011;6(12):e28632.
Guenaga J, Dosenovic P, Ofek G, Baker D, Schief WR, Kwong PD, et al. Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLoS ONE. 2011;6(1):e16074.
Radebe M, Nair K, Chonco F, Bishop K, Wright JK, van der Stok M, et al. Limited immunogenicity of HIV CD8+ T-cell epitopes in acute Clade C virus infection. J Infect Dis. 2011;204(5):768-76.
Novitsky V, Ndung'u T, Wang R, Bussmann H, Chonco F, Makhema J, et al. Extended high viremics: a substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection. AIDS. 2011;25(12):1515-22.
Wright JK, Novitsky V, Brockman MA, Brumme ZL, Brumme CJ, Carlson JM, et al. Influence of Gag-protease-mediated replication capacity on disease progression in individuals recently infected with HIV-1 subtype C. J Virol. 2011;85(8):3996-4006.
Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, Shukair S, et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature. 2010;467(7315):591-5.
Reyes-Teran G, Butera ST. Preventing influenza coinfection among HIV-infected persons: a complex picture coming into focus. AIDS. 2010;24(14):2283-5.
Pietzsch J, Scheid JF, Mouquet H, Klein F, Seaman MS, Jankovic M, et al. Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness. J Exp Med. 2010;207(9):1995-2002.
Menendez A, Calarese DA, Stanfield RL, Chow KC, Scanlan CN, Kunert R, et al. A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120. FASEB J. 2008;22(5):1380-92.
Scanlan CN, Calarese DA, Lee H-, Blixt O, Wong C-, Wilson I, et al. Antibody recognition of a carbohydrate epitope: a template for HIV vaccine design. Adv Exp Med Biol. 2005;564:7-8.
Crotty S, Andino R. Poliovirus vaccine strains as mucosal vaccine vectors and their potential use to develop an AIDS vaccine. Adv Drug Deliv Rev. 2004;56(6):835-52.
Svenson T, Berg S. [Experimentation with altered nursing care in the management of seriously ill geriatric patients (proceedings)]. Aktuelle Gerontol. 1978;8(10):556-7.
Bland RD, Clarke TL, Harden LB. Rapid infusion of sodium bicarbonate and albumin into high-risk premature infants soon after birth: a controlled, prospective trial. Am J Obstet Gynecol. 1976;124(3):263-7.
Renaud B, Buda M, Lewis BD, Pujol JF. Effects of 5,6-dihydroxytryptamine on tyrosine-hydroxylase activity in central catecholaminergic neurons of the rat. Biochem Pharmacol. 1975;24(18):1739-42.
Lefkowitz RJ. Identification of adenylate cyclase-coupled beta-adrenergic receptors with radiolabeled beta-adrenergic antagonists. Biochem Pharmacol. 1975;24(18):1651-8.
Schmoldt A, Benthe HF, Haberland G. Digitoxin metabolism by rat liver microsomes. Biochem Pharmacol. 1975;24(17):1639-41.
Bose KS, Sarma RH. Delineation of the intimate details of the backbone conformation of pyridine nucleotide coenzymes in aqueous solution. Biochem Biophys Res Commun. 1975;66(4):1173-9.
Wiesmann UN, DiDonato S, Herschkowitz NN. Effect of chloroquine on cultured fibroblasts: release of lysosomal hydrolases and inhibition of their uptake. Biochem Biophys Res Commun. 1975;66(4):1338-43.
Ris MM, Deitrich RA, Von Wartburg JP. Inhibition of aldehyde reductase isoenzymes in human and rat brain. Biochem Pharmacol. 1975;24(20):1865-9.
Barthel W, Markwardt F. Aggregation of blood platelets by adrenaline and its uptake. Biochem Pharmacol. 1975;24(20):1903-4.
Tarentino AL, Maley F. A comparison of the substrate specificities of endo-beta-N-acetylglucosaminidases from Streptomyces griseus and Diplococcus Pneumoniae. Biochem Biophys Res Commun. 1975;67(1):455-62.
Garner CW, Behal FJ. Effect of pH on substrate and inhibitor kinetic constants of human liver alanine aminopeptidase. Evidence for two ionizable active center groups. Biochemistry. 1975;14(23):5084-8.
Makar AB, McMartin KE, Palese M, Tephly TR. Formate assay in body fluids: application in methanol poisoning. Biochem Med. 1975;13(2):117-26.
[Health and nursing care's working environment should be critically examined. Contribution to the discussion about working environment as an introduction to the congress]. Sygeplejersken. 1975;75(49):17.